---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-23-000039"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:46:21.591630+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity

## Summary
- Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.
- Cash, equivalents & investments $89.5M as of June 30, 2023; plus $75M gross from July follow-on offering extends runway into H1 2025.
- BDTX-1535 Phase 1 dose-escalation showed confirmed partial responses in 5 of 12 evaluable NSCLC patients; expansion cohorts initiated July 2023.
- Phase 1 trial for BDTX-4933 (BRAF/RAS inhibitor) initiated in Q2 2023; GBM dose-escalation update expected Q4 2023.
- FDA meeting planned in Q4 2023 to discuss accelerated approval pathway for BDTX-1535 in NSCLC.

## SEC filing metadata
- accession: 0001701541-23-000039
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/0001701541-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/bdtx-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-23-000039
- JSON: https://secwatch.observer/filing/0001701541-23-000039.json
- Plain text: https://secwatch.observer/filing/0001701541-23-000039.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Black Diamond Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/0001701541-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.